Dunkin', Canon: 5 Top Stock Gainers for Monday

Dunkin', Silvergate Capital, Mirati Therapeutics, Canon and AnaptysBio are five of the top stock gainers for Monday.
Author:
Publish date:

Stocks ended sharply Monday amid stalled stimulus negotiations, rising coronavirus infections, and the impending presidential elections.

Here are some of the market's biggest gainers for Monday:

1. Dunkin' | Percentage Increase Over 16%

Dunkin'  (DNKN) - Get Report shares moved up after the Dunkin' Donuts and Baskin-Robbins operator said it was looking at a potential $9 billion sale to Inspire Brands, which owns several chains including Arby's.  The cost negotiated to take Dunkin' private is a share price of $106.50, according to the New York Times.

2. Silvergate Capital | Percentage Increase Over 8%

Silvergate Capital  (SI) - Get Report climbed after the financial services company beat Wall Street's third-quarter earnings expectations. Net income for the quarter was $7.1 million, or 37 cents per share, compared with net income of $6.7 million, or 36 cents, in the year-earlier period.

3. Mirati Therapeutics | Percentage Increase Over 9%

Mirati Therapeutics  (MRTX) - Get Report advanced after the clinical-stage oncology company reported positive preliminary data on Sunday from Phase 1/2 clinical studies of adagrasib, an experimental drug designed to treat advanced non-small-cell lung cancer. Several analysts raised their price targets following the announcement. 

4. Canon | Percentage Increase Over 7%

Canon  (CAJ) - Get Report rose after the Tokyo camera and office machine maker beat Wall Street's third-quarter earnings estimates. Earnings per share were down 35% over the past year to $0.15, which beat the estimate of $0.01. Revenue was down 11% but still exceeded analysts' forecasts.

5. AnaptysBio | Percentage Increase Over 7%

Shares of AnaptysBio  (ANAB) - Get Report were climbing after the biotech said it had amended its agreement with GlaxoSmithKline  (GSK) - Get Report. The deal provides AnaptysBio with increased royalties on sales of the anti-tumor drug dostarlimab, a royalty on GSK’s Zejula and a one-time cash payment. Zejula treats epithelial ovarian, fallopian tube, or primary peritoneal cancer.